These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35715573)

  • 1. Clinical efficacy of urea treatment in syndrome of inappropriate antidiuretic hormone secretion.
    Perelló-Camacho E; Pomares-Gómez FJ; López-Penabad L; Mirete-López RM; Pinedo-Esteban MR; Domínguez-Escribano JR
    Sci Rep; 2022 Jun; 12(1):10266. PubMed ID: 35715573
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, double blinded, placebo-controlled trial to evaluate the efficacy and safety of tolvaptan in Chinese patients with hyponatremia caused by SIADH.
    Chen S; Zhao JJ; Tong NW; Guo XH; Qiu MC; Yang GY; Liu ZM; Ma JH; Zhang ZW; Gu F
    J Clin Pharmacol; 2014 Dec; 54(12):1362-7. PubMed ID: 24906029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rapidity of Correction of Hyponatremia Due to Syndrome of Inappropriate Secretion of Antidiuretic Hormone Following Tolvaptan.
    Morris JH; Bohm NM; Nemecek BD; Crawford R; Kelley D; Bhasin B; Nietert PJ; Velez JCQ
    Am J Kidney Dis; 2018 Jun; 71(6):772-782. PubMed ID: 29478867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Efficacy of Tolvaptan in Korean Patients with Hyponatremia Caused by the Syndrome of Inappropriate Antidiuretic Hormone.
    Han SW; Yi JH; Kang KP; Kim HY; Kim SW; Choi HY; Ha SK; Kim GH; Kim YW; Jeong KH; Shin SK; Kim HJ
    J Korean Med Sci; 2018 Apr; 33(15):e112. PubMed ID: 29629516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Using Tolvaptan to Treat Hyponatremia: Results from a Post-authorization Pharmacovigilance Study.
    Estilo A; McCormick L; Rahman M
    Adv Ther; 2021 Dec; 38(12):5721-5736. PubMed ID: 34693505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
    Gralla RJ; Ahmad F; Blais JD; Chiodo J; Zhou W; Glaser LA; Czerwiec FS
    Cancer Med; 2017 Apr; 6(4):723-729. PubMed ID: 28251822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-life experience of tolvaptan use in the treatment of severe hyponatraemia due to syndrome of inappropriate antidiuretic hormone secretion.
    Tzoulis P; Waung JA; Bagkeris E; Carr H; Khoo B; Cohen M; Bouloux PM
    Clin Endocrinol (Oxf); 2016 Apr; 84(4):620-6. PubMed ID: 26385871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In-patient Tolvaptan use in SIADH: care audit, therapy observation and outcome analysis.
    Humayun MA; Cranston IC
    BMC Endocr Disord; 2017 Nov; 17(1):69. PubMed ID: 29110656
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tolvaptan on hyponatremia in a dog with syndrome of inappropriate secretion of antidiuretic hormone.
    Yamamoto H; Kimura K; Horikirizono H; Tamura Y; Kambayashi S; Baba K; Okuda M; Mizuno T; Igase M
    J Vet Med Sci; 2023 Oct; 85(10):1047-1051. PubMed ID: 37587049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tolvaptan and urea in paediatric hyponatraemia.
    Veligratli F; Alexandrou D; Shah S; Amin R; Dattani M; Gan HW; Famuboni A; Lopez-Garcia C; Trompeter R; Bockenhauer D
    Pediatr Nephrol; 2024 Jan; 39(1):177-183. PubMed ID: 37466863
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.
    Hagiwara D; Matsukawa M; Tasaki J; Nakamura Y; Arima H
    Endocr J; 2023 Dec; 70(12):1195-1205. PubMed ID: 37914256
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SIADH-related hyponatremia in hospital day care units: clinical experience and management with tolvaptan.
    De Las Peñas R; Ponce S; Henao F; Camps Herrero C; Carcereny E; Escobar Álvarez Y; Rodríguez CA; Virizuela JA; López López R
    Support Care Cancer; 2016 Jan; 24(1):499-507. PubMed ID: 26431960
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of Urea for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: A Systematic Review.
    Wendt R; Fenves AZ; Geisler BP
    JAMA Netw Open; 2023 Oct; 6(10):e2340313. PubMed ID: 37902751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World, Non-Interventional, Retrospective Study (SAMPLE) of Tolvaptan in Patients with Hyponatraemia Secondary to the Syndrome of Inappropriate Antidiuretic Hormone Secretion.
    Pose-Reino A; Runkle de la Vega I; de Jong-Laird A; Kabra M; Lindner U
    Adv Ther; 2021 Feb; 38(2):1055-1067. PubMed ID: 33306187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-dose tolvaptan for the treatment of hyponatremia in the syndrome of inappropriate ADH secretion (SIADH).
    Harbeck B; Lindner U; Haas CS
    Endocrine; 2016 Sep; 53(3):872-3. PubMed ID: 26961548
    [No Abstract]   [Full Text] [Related]  

  • 16. Efficacy and tolerance of urea compared with vaptans for long-term treatment of patients with SIADH.
    Soupart A; Coffernils M; Couturier B; Gankam-Kengne F; Decaux G
    Clin J Am Soc Nephrol; 2012 May; 7(5):742-7. PubMed ID: 22403276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Uric acid levels with tolvaptan treatment for syndrome of inappropriate antidiuretic hormone secretion.
    Nagamine T
    Endocrine; 2024 Mar; 83(3):826-827. PubMed ID: 37982946
    [No Abstract]   [Full Text] [Related]  

  • 18. Tolvaptan is successful in treating inappropriate antidiuretic hormone secretion in infants.
    Marx-Berger D; Milford DV; Bandhakavi M; Van't Hoff W; Kleta R; Dattani M; Bockenhauer D
    Acta Paediatr; 2016 Jul; 105(7):e334-7. PubMed ID: 27028950
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment with urea as an alternative to tolvaptan for the syndrome of inappropriate secretion of antidiuretic hormone].
    Gómez Valbuena I; Alonso Pérez L; Alioto D; Cañamares Orbis I; Ferrari Piquero JM
    Farm Hosp; 2014 Jul; 38(4):379-80. PubMed ID: 25137170
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of tolvaptan for the treatment of hyponatraemia secondary to syndrome of inappropriate antidiuretic hormone secretion in Sweden.
    Jamookeeah C; Robinson P; O'Reilly K; Lundberg J; Gisby M; Ländin M; Skov J; Trueman D
    BMC Endocr Disord; 2016 May; 16(1):22. PubMed ID: 27184496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.